Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Citi
Medtronic
Baxter
Chinese Patent Office
Queensland Health
McKinsey
McKesson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Hetacillin potassium - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for hetacillin potassium and what is the scope of hetacillin potassium freedom to operate?

Hetacillin potassium
is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for hetacillin potassium.
Summary for hetacillin potassium
Synonyms for hetacillin potassium
26939-80-0
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, monopotassium salt, (2S-(2alpha,5alpha,6beta(S*)))-
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-imidazolinyl)-3,3-dimethyl-7-oxo-, monopotassium salt
4052-56-6
5321-32-4
6alpha-(2,2-Dimethyl-5-oxo-4-phenylimidazolidin-1-yl)penicillanic acid potassium salt
95PFX5932Y
AC1Q1U2K
AKOS030526838
C13980
C19H22N3O4S.K
CAS-5321-32-4
CCG-39645
CHEBI:34789
CHEMBL1201121
CHEMBL3186897
CS-4871
D02203
DSSTox_CID_25830
DSSTox_GSID_45830
DSSTox_RID_81158
DTXSID0045830
EINECS 226-182-3
H-K Mastitis (Veterinary)
HE349277
Hetacillin (potassium)
Hetacillin potassium (JAN/USAN)
Hetacillin potassium [USAN:JAN]
Hetacillin potassium [USAN:USP:JAN]
Hetacin-k (TN)
Hetacin-K (Veterinary)
HMS1920D05
HMS2091J11
HMS500A05
HY-16251
LS-149854
Natacillin
NCGC00094692-01
Potassium (2S-(2alpha,5alpha,6beta(S*)))-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
potassium (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
POTASSIUM [2S-[2A,5A,6BETA(S*)]]-6-(2,2-DIMETHYL-5-OXO-4-PHENYLIMIDAZOLIDIN-1-YL)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLATE
Potassium 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
potassium 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylate
potassium 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanate
Potassium hetacillin
potassium(2s,5r)-6-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
SCHEMBL192601
SCHEMBL719623
SPECTRUM1500327
Tox21_111315
UNII-95PFX5932Y
Versapen-k

US Patents and Regulatory Information for hetacillin potassium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol VERSAPEN-K hetacillin potassium CAPSULE;ORAL 061396-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol VERSAPEN-K hetacillin potassium CAPSULE;ORAL 061396-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
McKinsey
Federal Trade Commission
Moodys
McKesson
Johnson and Johnson
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.